High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4.2M
$4,219,553
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
Other
|
2026-04-01 | $108,750 | M | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-04-01 | $370,076x2 | S | Form 4 |
|
SYRE
M
Spyre Therapeutics, Inc.
Sloan Sheldon
• Officer • Chief Medical Officer
Other
2026-04-01
$172,370
|
||||||
| SYRE |
Spyre Therapeutics, Inc.
|
Officer • Chief Medical Officer
Other
|
2026-04-01 | $172,370 | M | Form 4 |
|
SYRE
S
Spyre Therapeutics, Inc.
Sloan Sheldon
• Officer • Chief Medical Officer
10b5-1 Sell
2026-04-01
$397,900
|
||||||
| SYRE |
Spyre Therapeutics, Inc.
|
Officer • Chief Medical Officer
10b5-1 Sell
|
2026-04-01 | $397,900 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-04-01 | $739,912x2 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
Other
|
2026-03-03 | $36,250 | M | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-03-03 | $101,620x2 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-03-02 | $632,866x2 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-02-02 | $492,045x2 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-12-01 | $435,356x2 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-11-03 | $1,049,778Largex2 | S | Form 4 |